Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction

Anti-Cancer Drugs

Volumn 12, Issue 7, 2001, Pages 619-625

  Ong, Simon Y K ^a   Clarke, Stephen J ^a   Bishop, James ^a   Dodds, Helen M ^b   Rivory, Laurent P ^a,b  

^a SYDNEY CANCER CENTRE   (Australia)

^b University of Sydney   (Australia)

Author keywords

Conjugation; Drug excretion; Irinotecan; Pharmacokinetic; Toxicity

Indexed keywords

IRINOTECAN;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COLORECTAL CARCINOMA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG EXCRETION; DRUG HALF LIFE; HEPATORENAL SYNDROME; HUMAN; LIVER FUNCTION; MALE; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ADENOCARCINOMA; ADENOMATOUS POLYPOSIS COLI PROTEIN; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CECAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; HUMANS; KIDNEY; KIDNEY DISEASES; LIVER; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 0034886371     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200108000-00009     Document Type: Article

References (53)

1. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
2. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy
3. Irinotecan versus infusional 5-fluorouracil: A phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil
4. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
5. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
6. Irinotecan combined with fluorouracil compared with fluorouracil alone as firstline treatment for metastatic colorectal cancer: A multicentre randomised trial
7. Irinotecan in cancers of the lung and cervix
8. Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers
9. CPT-11 in gastrointestinal cancer
10. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer
11. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
12. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
13. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer
14. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of firstline irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix
15. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions
16. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase
17. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms
18. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2
19. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
20. Irinotecan (CPT-11) metabolites in human bile and urine
21. Irinotecan (CPT-11) metabolism and disposition in cancer patients
22. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients
23. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients
24. Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes
25. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions
26. Identification of a new metabolite of CPT-11 (irinotecan): Pharmacological properties and activation to SN-38
27. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
28. Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports
29. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
30. Trace analysis of SN-38 in human plasma by high-performance liquid chromatography
31. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma
32. Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance
33. Irinotecan (CPT-11): A prelimary investigation of the relationship between trough concentrations of the active metabolite, SN-38, and toxicity
34. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix
35. Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients
36. Colorectal cancer: Dilemmas regarding patient selection and toxicity prediction
37. Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: A need for guidelines
38. Bradycardia induced by irinotecan: A case report
39. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer
40. Risk factors of pneumonitis following chemoradiotherapy for lung cancer
41. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer
42. Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment (CPT-11)
43. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure
44. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
45. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials
46. Factors involved in prolongation of the terminal disposition phase of SN-38: Clinical and experimental studies
47. Total plasma clearance of irinotecan (CPT-11) correlates with both alkaline phosphatase and bilirubin levels in patients with tumoral hepatic involvement
48. Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters
49. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats
50. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines
51. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: Role of canalicular multispecific organic anion transporter and P-glycoprotein
52. Zonal downregulation and redistribution of the multidrug resistance protein 2 during bile duct ligation in rat liver
53. Endotoxin downregulates hepatic expression of P-glycoprotein and MRP2 in 2-acetylaminofluorene-treated rats